Neutralizing antibody titers after COVID-19 vaccination

IF 2.3 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Clinical Epidemiology and Global Health Pub Date : 2024-11-01 DOI:10.1016/j.cegh.2024.101819

Safoora Shirani Shams Abadi, Laleh Hoveida, Nafiseh Sadat Naghavi

{"title":"Neutralizing antibody titers after COVID-19 vaccination","authors":"Safoora Shirani Shams Abadi, Laleh Hoveida, Nafiseh Sadat Naghavi","doi":"10.1016/j.cegh.2024.101819","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Monitoring COVID-19 and evaluating the effectiveness of prevention and control strategies are considered critical priorities in public health. As a result, the administration of COVID-19 vaccines has been widely approved around the world. In the current study, we investigated the level of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) neutralizing antibody (NAb) among individuals who received different COVID-19 vaccines.</div></div><div><h3>Methods</h3><div>This cross-sectional study recorded demographical data and clinical characteristics of 168 individuals who received COVID-19 vaccines from 2021 to 2022. Vaccination data of participants, including type and times of vaccine and any complications and symptoms after vaccination, were also recorded. SARS-CoV-2 NAb level was assessed by performing an ELISA test, and all data was analyzed using SPSS version 21. The significant level was set at 0.05.</div></div><div><h3>Results</h3><div>The mean age of the participants was 40.4 ± 16 years, and 109 were females. About 18.4 % of participants had the underlying diseases, of which thyroid diseases were the most frequent. The mean SARS-CoV-2 NAb level was 31.6 ± 39.78 ng/ml. Sinopharm was the common vaccine in our population, and AstraZeneca represented a high level of Nab 47.18 ng/ml. Among the participants, 96 had mild to severe complications after vaccination, with the most complaining of arm pain. Significant differences of NAb levele were observed only between types of vaccine and gender (P < 0.05).</div></div><div><h3>Conclusion</h3><div>Due to our findings, all employed vaccines demonstrated efficacy in generating NAb. The levels of Nab were different among genders, age groups, and different types of vaccine receivers.</div></div>","PeriodicalId":46404,"journal":{"name":"Clinical Epidemiology and Global Health","volume":"30 ","pages":"Article 101819"},"PeriodicalIF":2.3000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Epidemiology and Global Health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213398424003166","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Monitoring COVID-19 and evaluating the effectiveness of prevention and control strategies are considered critical priorities in public health. As a result, the administration of COVID-19 vaccines has been widely approved around the world. In the current study, we investigated the level of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) neutralizing antibody (NAb) among individuals who received different COVID-19 vaccines.

Methods

This cross-sectional study recorded demographical data and clinical characteristics of 168 individuals who received COVID-19 vaccines from 2021 to 2022. Vaccination data of participants, including type and times of vaccine and any complications and symptoms after vaccination, were also recorded. SARS-CoV-2 NAb level was assessed by performing an ELISA test, and all data was analyzed using SPSS version 21. The significant level was set at 0.05.

Results

The mean age of the participants was 40.4 ± 16 years, and 109 were females. About 18.4 % of participants had the underlying diseases, of which thyroid diseases were the most frequent. The mean SARS-CoV-2 NAb level was 31.6 ± 39.78 ng/ml. Sinopharm was the common vaccine in our population, and AstraZeneca represented a high level of Nab 47.18 ng/ml. Among the participants, 96 had mild to severe complications after vaccination, with the most complaining of arm pain. Significant differences of NAb levele were observed only between types of vaccine and gender (P < 0.05).

Conclusion

Due to our findings, all employed vaccines demonstrated efficacy in generating NAb. The levels of Nab were different among genders, age groups, and different types of vaccine receivers.

查看原文本刊更多论文

接种 COVID-19 疫苗后的中和抗体滴度

背景监测 COVID-19 和评估预防与控制策略的有效性被认为是公共卫生领域的关键优先事项。因此，COVID-19 疫苗已在全球范围内得到广泛批准。本研究调查了接种不同 COVID-19 疫苗的人群中严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）中和抗体（NAb）的水平。研究还记录了参与者的疫苗接种数据，包括疫苗类型和接种时间以及接种后的并发症和症状。通过酶联免疫吸附试验评估 SARS-CoV-2 NAb 水平，并使用 SPSS 21 版分析所有数据。结果参与者的平均年龄为（40.4 ± 16）岁，其中女性 109 人。约 18.4% 的参与者患有基础疾病，其中以甲状腺疾病最为常见。SARS-CoV-2 NAb 的平均水平为 31.6 ± 39.78 纳克/毫升。国药集团是我们人群中常见的疫苗，阿斯利康代表了较高的 NAb 水平（47.18 纳克/毫升）。参与者中有 96 人在接种后出现了轻度至严重的并发症，其中以手臂疼痛为主诉。结论根据我们的研究结果，所有使用的疫苗都显示出产生 NAb 的功效。不同性别、年龄组和不同类型疫苗接种者的 NAb 水平均有所不同。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Epidemiology and Global Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

4.60

自引率

7.70%

发文量

218

审稿时长

66 days

期刊介绍： Clinical Epidemiology and Global Health (CEGH) is a multidisciplinary journal and it is published four times (March, June, September, December) a year. The mandate of CEGH is to promote articles on clinical epidemiology with focus on developing countries in the context of global health. We also accept articles from other countries. It publishes original research work across all disciplines of medicine and allied sciences, related to clinical epidemiology and global health. The journal publishes Original articles, Review articles, Evidence Summaries, Letters to the Editor. All articles published in CEGH are peer-reviewed and published online for immediate access and citation.